Ind-Swift Ltd

Ind-Swift, a microcap in the Pharmaceuticals & Drugs sector, has hit a new 52-week low, reflecting significant volatility and a 9.02% decline over two days. The stock has underperformed its sector and is trading below key moving averages, indicating ongoing challenges in the market.

Ind-Swift, a microcap in the Pharmaceuticals & Drugs sector, has reached a new 52-week low, reflecting a year-over-year decline. Despite recent gains after a week of losses, the stock remains below key moving averages, highlighting ongoing challenges in its performance amid broader market trends.

Ind-Swift, a microcap in the Pharmaceuticals & Drugs sector, has hit a new 52-week low amid a seven-day losing streak, resulting in a 22.59% decline. The stock has underperformed its sector and is trading below key moving averages, reflecting ongoing challenges in a competitive market.

Ind-Swift, a microcap company in the Pharmaceuticals & Drugs sector, announced its financial results for Q3 FY24-25, revealing stable performance. However, the company's evaluation score has significantly declined over the past three months, indicating a shift in the assessment of its financial health and operational effectiveness.

Ind-Swift, a microcap in the Pharmaceuticals & Drugs sector, has hit a new 52-week low, marking six consecutive days of decline and an 18.54% drop during this period. The stock has underperformed its sector and declined 23.09% over the past year, contrasting with the Sensex's gains.

Ind-Swift, a microcap in the Pharmaceuticals & Drugs sector, has hit a new 52-week low, reflecting significant volatility and a 17.89% decline over the past five days. The stock has underperformed its sector and is trading below key moving averages, indicating ongoing challenges in a competitive market.

Ind-Swift has recently been added to MarketsMOJO's list following a revision in its score, reflecting the stock's performance metrics and market position. Despite reaching a 52-week high earlier this month, the stock has faced short-term challenges, underperforming its sector and experiencing a decline over the past two days. However, its long-term trend remains positive, with significant annual returns.

Ind-Swift has recently experienced a revision in its score, reflecting its strong market performance and upward momentum. The stock reached a new 52-week high, outperforming its sector significantly. Additionally, it has been added to MarketsMOJO's list, underscoring its impressive annual return and positive trading indicators.

Ind-Swift has recently been added to MarketsMOJO's list following a revision in its score, reflecting the stock's strong performance metrics. The company has achieved a new 52-week high and has consistently outperformed its sector, showcasing impressive returns over the past year and a notable gain in recent trading sessions.

Ind-Swift has recently undergone a revision in its score, reflecting changes in market dynamics. Despite a notable performance over the past year, the stock has faced a trend reversal after reaching a new 52-week high. It has been added to MarketsMOJO's list, indicating ongoing interest in its potential.

Ind-Swift has recently experienced a notable adjustment in its evaluation, reflecting its strong market performance and significant price surge. The stock has been added to MarketsMOJO's list, highlighting its impressive returns and consistent outperformance against the sector and broader market indices. Investors are keenly observing this microcap pharmaceutical company.

Ind-Swift, a microcap pharmaceutical company, has reported positive financial results for the second quarter of fiscal year 2024-2025, despite a 'Sell' call from MarketsMOJO. The company's score has improved from 5 to 8, with high operating profit to interest ratio and net sales. However, there are concerns regarding falling PAT and operating cash flow.

Ind-Swift, a microcap pharmaceutical company, has reported a flat performance in the quarter ending June 2024, with a score of 5 out of 11. While the Profit After Tax has shown significant growth, the Profit Before Tax and Net Sales have decreased. The company's Operating Profit and Efficiency have also declined. Non Operating Income is high, indicating a potentially unsustainable business model. Investors should carefully evaluate these factors before making any decisions.

Ind-Swift, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on April 9th, 2024. The stock has outperformed its sector by 5.78% and has gained 57.73% in the last 5 days. It is currently trading above its moving averages and has shown a remarkable 1-year performance of 241.50%.

Ind-Swift, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high of Rs.28.27 on April 8, 2024. The stock has gained an impressive 48.63% in the past four days, outperforming the sector by 19.66%. This can be attributed to the company's strong financial performance and positive market sentiment.

Ind-Swift, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on February 8th, 2024. Despite being given a 'Strong Sell' rating by MarketsMOJO, the company has outperformed its sector and shown consecutive gains in the last 3 days. With a strong performance and positive trend, Ind-Swift has potential for growth in the pharmaceutical industry.

Ind-Swift, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on February 7th, 2024. Despite a 'Strong Sell' rating from MarketsMOJO, the stock has outperformed the sector by 7.32% and has shown consecutive gains in the past two days. It is currently trading higher than its moving averages and has a remarkable 1-year performance of 126.29%, showcasing its strong growth potential.

Ind-Swift, a microcap pharmaceutical company, has reached a 52-week high on January 15, 2024. However, according to MarketsMOJO, the stock has been given a Strong Sell rating. It has underperformed the sector today and experienced a trend reversal. Despite recent gains, its one-year performance has been impressive, outperforming the Sensex. Investors should carefully consider their options before investing.

Ind-Swift, a microcap pharmaceutical company, has reported a decline in net sales and consolidated net profit for the quarter ended September 2023. The company's operating profit and interest expenses have also decreased, leading to a negative score of -6. However, net sales for the half-yearly period have shown growth, but PBT and PAT have declined. MarketsMOJO has given a 'Strong Sell' call for the company's stock.